Literature DB >> 29330836

Pathogenesis of non-alcoholic fatty liver disease mediated by YAP.

Ping Chen1, Qihui Luo1,2, Chao Huang1, Qi Gao1, Like Li1, Jingfei Chen1, Bing Chen1, Wentao Liu1,2, Wen Zeng3, Zhengli Chen4,5.   

Abstract

OBJECTIVE: This study aimed to investigate the mechanism of the interaction between Yes-associated protein (YAP) and transforming growth factor-β (TGF-β)/Smad signaling pathways in the development of non-alcoholic fatty liver disease (NAFLD).
METHODS: Serum samples of monkeys with biopsy-proven NAFLD and healthy normal monkeys were used to measure fasting plasma glucose (FPG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG) and albumin (ALB) with the BECKMAN CX5 PRO. Hematoxylin-eosin staining (H&amp;E) was used for pathologic analysis, Masson trichrome staining was used to assess for fibrosis staging, and Oil Red O staining was used to detect lipid droplet deposition. According to an NAFLD activity score of < 4 points and > 4 points, the samples were divided into groups: the steatosis group and fibrosing NASH group. Furthermore, monkeys with a fibrosis stage < 2 were assigned to the mild fibrosis group, while monkeys with fibrosis stage ≥ 2 were assigned to the significant fibrosis group. Moreover, the fibrosis stage was subdivided as follows: stages 1a, 1c and 2-3. Immunohistochemistry and real-time quantitative PCR were used to quantify protein and gene expression, respectively.
RESULTS: In the present study, 54 monkeys with NAFLD and 23 normal monkeys were recruited. Serum FPG and TG levels were higher in fibrosing NASH monkeys compared with simple steatosis and normal monkeys, and differences between simple steatosis and normal monkeys were not statistically significant (p > 0.05). YAP increased in NAFLD, which mainly localized in the nuclei of hepatocytes, perivascular cells and bile duct cells; the accumulation of YAP correlated with the severity of hepatocyte injury. Compared with normal monkeys, the expression of TGF-β, α-smooth muscle actin (α-SMA), Drosophila mothers against decapentaplegic protein 3 (Smad3) and connective tissue growth factor (CTGF) in the liver of simple steatosis monkeys significantly increased (p < 0.01). Compared with simple steatosis monkeys, the expression of TGF-β, α-SMA, Smad3 and CTGF in fibrosing NASH significantly increased (p < 0.01). However, the expression of Drosophila mothers against decapentaplegic protein 7 (Smad7) in the liver of fibrosing NASH monkeys significantly decreased (p < 0.01). With the severity of liver fibrosis, the expression of TGF-β, α-SMA, Smad3 and CTGF gradually increased, and the difference was statistically significant (p < 0.01). However, there was no significant difference in the expression of Smad3 between fibrosis stage 1a and 1c. Compared with normal monkeys, the expression of Smad7 in the liver of monkeys with fibrosis significantly decreased (p < 0.01), but was significantly higher at fibrosis stage 1c than at fibrosis stage 1a and 2.
CONCLUSION: The YAP and TGF-β signaling pathways and the interaction between them promote the development and progression of NAFLD.

Entities:  

Keywords:  Hepatic fibrosis; NAFLD; NASH; TGF-β; YAP

Mesh:

Substances:

Year:  2018        PMID: 29330836     DOI: 10.1007/s12072-017-9841-y

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  21 in total

1.  Crosstalk between Hippo and TGFβ: Subcellular Localization of YAP/TAZ/Smad Complexes.

Authors:  Karin Grannas; Linda Arngården; Peter Lönn; Magdalena Mazurkiewicz; Andries Blokzijl; Agata Zieba; Ola Söderberg
Journal:  J Mol Biol       Date:  2015-05-01       Impact factor: 5.469

2.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

3.  Prevalence of and risk factors for fatty liver in a general population of Shanghai, China.

Authors:  Jian-Gao Fan; Jun Zhu; Xing-Jian Li; Lan Chen; Lui Li; Fei Dai; Feng Li; Shi-Yao Chen
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

4.  Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation.

Authors:  Jin H Li; Hong-Jian Zhu; Xiao R Huang; Kar N Lai; Richard J Johnson; Hui Y Lan
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

5.  YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal Fibrogenesis.

Authors:  Stephen G Szeto; Masahiro Narimatsu; Mingliang Lu; Xiaolin He; Ahmad M Sidiqi; Monica F Tolosa; Lauren Chan; Krystale De Freitas; Janne Folke Bialik; Syamantak Majumder; Stellar Boo; Boris Hinz; Qinghong Dan; Andrew Advani; Rohan John; Jeffrey L Wrana; Andras Kapus; Darren A Yuen
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

6.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

7.  Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease.

Authors:  Miriam B Vos; Shirish Barve; Swati Joshi-Barve; John D Carew; Peter F Whitington; Craig J McClain
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-10       Impact factor: 2.839

8.  Origin and function of myofibroblasts in kidney fibrosis.

Authors:  Valerie S LeBleu; Gangadhar Taduri; Joyce O'Connell; Yingqi Teng; Vesselina G Cooke; Craig Woda; Hikaru Sugimoto; Raghu Kalluri
Journal:  Nat Med       Date:  2013-06-30       Impact factor: 53.440

9.  Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.

Authors:  Michelle M Richardson; Julie R Jonsson; Elizabeth E Powell; Elizabeth M Brunt; Brent A Neuschwander-Tetri; Prithi S Bhathal; John B Dixon; Martin D Weltman; Herbert Tilg; Alexander R Moschen; David M Purdie; Anthony J Demetris; Andrew D Clouston
Journal:  Gastroenterology       Date:  2007-05-16       Impact factor: 22.682

10.  Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.

Authors:  Christine C Hsu; Juliane S Troeger; Ingmar Mederacke; Peter Huebener; Xueru Mu; Dianne H Dapito; Jean-Philippe Pradere; Robert F Schwabe
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  14 in total

Review 1.  Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.

Authors:  Anwesha Dey; Xaralabos Varelas; Kun-Liang Guan
Journal:  Nat Rev Drug Discov       Date:  2020-06-17       Impact factor: 84.694

2.  TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma.

Authors:  Jie Zhang; Pin Liu; Junyan Tao; Pan Wang; Yi Zhang; Xinhua Song; Li Che; Pavel Sumazin; Silvia Ribback; Andras Kiss; Zsuzsa Schaff; Antonio Cigliano; Frank Dombrowski; Carla Cossu; Rosa M Pascale; Diego F Calvisi; Satdarshan P Monga; Xin Chen
Journal:  Am J Pathol       Date:  2019-02-19       Impact factor: 4.307

3.  [Changes of YAP activity at the early stage of nonalcoholic steatohepatitis and its spatiotemporal relationship with ductular reaction in mice].

Authors:  Y Liu; J Liang; W Zeng; Y Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-09-20

Review 4.  New Insights into Hippo/YAP Signaling in Fibrotic Diseases.

Authors:  Masum M Mia; Manvendra K Singh
Journal:  Cells       Date:  2022-06-29       Impact factor: 7.666

Review 5.  Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases.

Authors:  Minyang Fu; Dandan Peng; Tianxia Lan; Yuquan Wei; Xiawei Wei
Journal:  Acta Pharm Sin B       Date:  2022-01-19       Impact factor: 14.903

6.  Lipid droplets disrupt mechanosensing in human hepatocytes.

Authors:  LiKang Chin; Neil D Theise; Abigail E Loneker; Paul A Janmey; Rebecca G Wells
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-05-28       Impact factor: 4.052

7.  Maternal obesity accelerated non-alcoholic fatty liver disease in offspring mice by reducing autophagy.

Authors:  Shuguang Han; Feng Zhu; Xiaoxia Huang; Panpan Yan; Ke Xu; Fangfang Shen; Jiawen Sun; Zeyu Yang; Guoxi Jin; Yiqun Teng
Journal:  Exp Ther Med       Date:  2021-05-03       Impact factor: 2.447

8.  Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway.

Authors:  Weihong Wang; Yukai He; Qiuli Liu
Journal:  Mol Med Rep       Date:  2021-05-06       Impact factor: 2.952

9.  mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease.

Authors:  Marwa Matboli; Shaimaa H Gadallah; Wafaa M Rashed; Amany Helmy Hasanin; Nada Essawy; Hala M Ghanem; Sanaa Eissa
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

10.  Anti-inflammatory and hepatoprotective effects of exopolysaccharides isolated from Pleurotus geesteranus on alcohol-induced liver injury.

Authors:  Xinling Song; Zhonghai Liu; Jianjun Zhang; Qihang Yang; Zhenzhen Ren; Chen Zhang; Min Liu; Zheng Gao; Huajie Zhao; Le Jia
Journal:  Sci Rep       Date:  2018-07-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.